-
1 week ago | 
huffpost.com | Siddhi Mahatole |Mariam Sunny
June 13 (Reuters) - Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals’ REGN.O offer for the DNA-testing company in a bankruptcy auction. Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and the non-profit TTAM Research Institute.
-
2 weeks ago | 
marketscreener.com | Siddhi Mahatole |Mariam Sunny
Published on 06/13/2025 at 16:31, updated on 06/13/2025 at 17:20(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction. Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and the non-profit TTAM Research Institute.
-
2 weeks ago | 
sg.finance.yahoo.com | Siddhi Mahatole |Mariam Sunny
Siddhi Mahatole and Mariam Sunny Fri, 13 June 2025 at 1:30 pm GMT-7 1 min read In this article: By Siddhi Mahatole and Mariam Sunny (Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction. Last month, Regeneron agreed to buy the firm for $256 million, topping a $146 million bid from Wojcicki and the non-profit TTAM Research Institute.
-
2 weeks ago | 
cp24.com | Siddhi Mahatole |Mariam Sunny |Alan Barona
Amazon said on Friday its healthcare business will be divided into six new units as part of a restructuring effort, in a move that comes after recent top health executive departures. The company's chief medical officer, Sunita Mishra, stepped down last month, while Aaron Martin, who has been the vice president of the healthcare unit, is also set to step down.
-
2 weeks ago | 
today.westlaw.com | Shinjini Ganguli |Anil D'Silva |Mariam Sunny
(Reuters) -Moderna's shares fell 2.3% on Friday on concerns about whether a new CDC advisory panel would back the use of the company's respiratory syncytial virus vaccine in a broader age group.
-
2 weeks ago | 
today.westlaw.com | Mariam Sunny |Siddhi Mahatole |Sriraj Kalluvila |Manya Saini
(Reuters) -Anne Wojcicki is set to regain control of 23andMe after a $305 million bid from a nonprofit she controls topped Regeneron Pharmaceuticals' offer for the DNA-testing company in a bankruptcy auction. Last month, Regeneron agreed to buy the...
-
3 weeks ago | 
today.westlaw.com | Manas Mishra |Shilpi Majumdar |Mariam Sunny
(Reuters) -Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition that can lead to vision loss, the European Medicines Agency's safety committee said on Friday.
-
3 weeks ago | 
ksl.com | Chandni Shah |Mariam Sunny |Christy Santhosh
SILVER SPRING, Md. — The Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, the company said on Saturday, the first endorsement since the regulator tightened requirements. The vaccine has also been approved for people aged 12 to 64 with at least one or more underlying risk factors defined by the Centers for Disease Control and Prevention, Moderna said in a statement.
-
1 month ago | 
941theduke.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
-
1 month ago | 
wimz.com | Mariam Sunny |Siddhi Mahatole
By Mariam Sunny and Siddhi Mahatole(Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has approved its meningococcal vaccine for use in infants as young as six weeks, making it the first shot intended for the age group. The vaccine, branded as MenQuadfi, is already approved for individuals aged two years and older to protect against the four most common strains of meningococcal bacteria – A, C, W and Y, the company said on Friday.
